Abstract Background: Interleukin‐1 receptor antagonist (IL‐1 Ra) levels are elevated early in
patients with acute myocardial infarction (MI) and often precede release of markers of …

Objectives: We sought to evaluate interleukin-1 receptor antagonist (IL-1Ra) levels in
patients with ST-segment elevation acute myocardial infarction (AMI) upon emergency …

Background: Increased plasma levels of acute phase reactants are correlated with acute
coronary syndromes and increased risk of in-hospital events. Interleukin-1 receptor …

Background Inhibition of the interleukin (IL)-1β innate immunity pathway is associated with
anti-inflammatory effects and a reduced risk of recurrent cardiovascular events in stable …

Two pilot studies of interleukin-1 (IL-1) blockade in ST-segment elevation myocardial
infarction (STEMI) showed blunted acute inflammatory response and overall favorable …

Background Little is known about the role of interleukin (IL) in patients with acute myocardial
infarction (MI), especially soluble IL-2 receptor (sIL-2R) and IL-8. We aim to evaluate, in MI …

Background ST‐segment–elevation myocardial infarction is associated with an intense
acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 …

Background: The plasma level of interleukin-6 (IL-6), a proinflammatory cytokine, has been
reported to be elevated in patients with acute myocardial infarction (AMI). In addition to a …

Ørn S, Ueland T, Manhenke C, Sandanger Ø, Godang K, Yndestad A, Mollnes TE, Dickstein
K, Aukrust P (Stavanger University Hospital, Stavanger; Oslo University Hospital …

Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …